Alain Chevallier has extensive experience in the pharmaceutical industry, to which he has devoted his entire professional career. With 30 years spent in the Sanofi Group, holding various management positions in subsidiaries abroad (Latin America, Japan) and Financial Director of Aventis Pharma SA then Sanofi Aventis France, he joined Truffle Capital in 2007 as Venture Partner then Partner in 2016.
In 2008, he co-founded Splicos SAS (now Abivax) with Truffle Capital, and as Chief Financial Officer led the IPO of Deinove in 2010, of Abivax in 2015, and as Chairman , that of Carbios in 2013.
He is a member of the Board of Directors of Carbios and Chairman of ArteDrone, Treasurer and Administrator of the ARC Foundation for Cancer Research. Alain graduated from HEC.